PentaBind

PentaBind applies generative AI to design and optimize aptamers—synthetic binding molecules for therapeutic and diagnostic use. The approach accelerates discovery cycles and improves target specificity by modeling molecular interactions in silico, reducing development time.
Founders
Rory Ryan
CEO
Rory is a third time founder. He cofounded ZiO Health, which he sold after leading it on product and operations for six years. With eight years of aptamer industry experience, he has first-hand customer experience of aptamer wet-labs. He graduated from the University of Leeds with a First Class in Engineering and a Distinction Master’s at Imperial College Business School.
Phil Haynes
CTO
Phil has five years of drug discovery experience in aptamers and cancer therapeutic, and holds a PhD in Molecular Biophysics from UCL and Imperial College. He has worked with multiple research institutes and pharma companies, including AstraZeneca. He holds a First Class degree in Physics from the University of Exeter.